Trial Research

 
News Articles for Trial Research top ^
2014/8/11
Important New Variable Covered.
Sign-up for NW BIO OBTAINS APPROVALS FOR ENHANCEMENTS OF PHASE III TRIAL OF DCVAX®-L FOR GBM BRAIN CANCER investment picks
Transcatheter Valve Durability Sustained Through Five Years WASHINGTON , Sept.
Sign-up for Significant Patient Benefits With Edwards Sapien Valve Demonstrated In 5-Year Partner Trial Data investment picks
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y. , Aug.
Sign-up for Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS , Aug.
Sign-up for Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced top line results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer (ExteNET Trial). The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer.
Sign-up for Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 Trial in Adjuvant Breast Cancer (ExteNET Trial) investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2). “Consistent with our long-standing development plans, this Phase 2 trial will compare the best dose of GEN-003 from our Phase 1/2a trial to other combinations of protein and adjuvant to determine the optimal dose for future trials and potentially improve on the current profile of GEN-003,” said Seth Hetherington, MD, chief medical officer of Genocea.
Sign-up for Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the Company’s Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro TM as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada.
Sign-up for ARCA biopharma Announces Health Canada Acceptance of Genetic-AF Clinical Trial Application investment picks
- Following intra-articular injection, sustained release of triamcinolone acetonide ( TCA) from FX006 maintained therapeutic concentration levels in knee joints of patients through 12 weeks - - Pharmacokinetic (PK) data support previously completed Phase 2b dose-ranging efficacy trial that demonstrated superior magnitude and duration of pain relief over 12 weeks compared to current standard of care - BURLINGTON, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced positive topline clinical trial results from a Phase 2a synovial fluid PK study of FX006, which demonstrated, for the first time, that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks.
Sign-up for Flexion Therapeutics Announces Positive Topline Results From Phase 2a Pharmacokinetic Trial With Lead Compound FX006 investment picks
- Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor - PARIS and TARRYTOWN, N.Y. , July 30, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator.
Sign-up for Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia investment picks
Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS , July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator.
Sign-up for Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia investment picks
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses Canada NewsWire BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer investment picks
PALO ALTO, Calif., June 26, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company") today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin TM for Knee Osteoarthritis (KOA). "We are pleased to reach this Company milestone and exceed enrollment of the forty-eight patients required for our Phase IIb clinical trial for Knee Osteoarthritis," said Dr.
Sign-up for Cellular Biomedicine Group Completes Enrollment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis investment picks
Bristol-Myers Squibb (NYSE:BMY) today announced a collaboration with Duke University through its Duke Clinical Research Institute (DCRI) focused on clinical trial transparency.
Sign-up for Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute investment picks
Huron Consulting Group (NASDAQ: HURN), a leading provider of business consulting services, today announced the launch of its trialRx tm service, a Huron Life Sciences clinical trial data monitoring service that helps pharmaceutical, biotechnology and medical device companies understand and mitigate clinical trial disclosure risks.
Sign-up for Huron Consulting Group Launches Clinical Trial Data Analytics and Visualization Service investment picks
CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its oral presentation given by Sant P.
Sign-up for Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology investment picks
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT.
Sign-up for XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder investment picks
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that positive top-line results from the lead-in portion of its IGNITE 2 clinical trial, a two-part Phase 3 clinical trial studying the efficacy and safety of intravenous (IV) and oral formulations of eravacycline for the treatment of complicated urinary tract infections (cUTI), support advancement of the trial into its pivotal portion.
Sign-up for Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion investment picks
LAVAL, Quebec, July 9, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the completion of two trials, the Phase II double-blind, placebo-controlled (TRIFECTA) study and the Pharmacokinetic (PK) trial.
Sign-up for Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Trial Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Trend Micro  |  Next: Trial Results